An increasing wave of product liability lawsuits has emerged across the US, accusing makers of popular GLP-1 drugs like Ozempic and Wegovy of causing sudden, permanent vision loss due to NAION. While some countries update warning labels, US courts grapple with scientific uncertainty and complex health risk factors in these cases.
Lawsuits accusing makers of popular GLP-1 medicines of causing sudden, permanent vision loss are multiplying across the US, turning an increasingly common class of weight-loss and diabetes drugs into the subject of a new wave of product liability claims. According to reports cited in the supplied material, patients in Arizona, New Jersey and Pennsylvania are arguing that medicines such as Ozempic, Wegovy, Zepbound and Mounjaro can trigger a rare eye disorder that leaves them with lasting damage.
The condition at the centre of the litigation is non-arteritic anterior ischaemic optic neuropathy, usually known as NAION. It occurs when blood flow to the optic nerve is interrupted, leading to sudden, painless loss of vision, most often in people over 50. Plaintiffs allege that drugmakers did not adequately warn US patients about that risk, even though updated labels in some other countries reportedly mention it.
The allegations have now spread far beyond a handful of isolated complaints. The lead report says dozens of cases have been filed in Arizona, nearly 100 in New Jersey and additional claims in Philadelphia. A separate summary from Arizona Family says hundreds of lawsuits have been lodged against Eli Lilly and Novo Nordisk, while a litigation-tracking site cited in the material says 146 plaintiffs had filed in the federal court in the Eastern District of Pennsylvania as of 19 July 2026.
Drugmakers are expected to fight the claims by pointing to other risk factors. Lawyers for Novo Nordisk have argued in court that many of the patients involved also have type 2 diabetes, which is already associated with a higher chance of eye disease and vision loss. That argument goes to a central question in the cases: whether the medications themselves are to blame, or whether the losses are better explained by underlying illness and other health risks.
Researchers, meanwhile, have cautioned that the evidence is still limited. The material supplied for this article says they do not yet have enough proof to conclude that Ozempic, Wegovy or Zepbound directly cause permanent blindness. That leaves the lawsuits to proceed against a backdrop of scientific uncertainty, commercial pressure and growing public concern over drugs that have transformed treatment for obesity and diabetes while also drawing scrutiny over a widening list of alleged side effects.
Disclaimer: This content is for informational purposes only and is not intended to be a substitute for professional medical judgment, advice, diagnosis, or treatment.
